Program

Συνεδρία poster – Ελαφρύ γεύμα

Tracks

Συνεδριακό και Πολιτιστικό Κέντρο Πανεπιστημίου Πατρών

Saturday, May 16, 2026

14:00 - 16:00

Speaker

Κωνσταντίνος Μαρίνος

Pharmacist, PhD candidate

PP01: The Role of Apolipoprotein A2 in Lipoprotein Metabolism, Development of Obesity, and Cardiovascular Disease

Κωνσταντίνα Σδούγκου

Διδακτρορική Φοιτήτρια

PP02: Developement of Novel Cinnamic Acid Derivatives as Promising Agents for Neurodegenerative Disorders

Ελευθέριος Μεζίλης

Φοιτητης

PP03: Platelet/Lymphocyte, Neutrophil/Lymphocyte, Monocyte/Lymphocyte Ratios and Systemic Immune-inflammation Index in Schizophrenia

Αλέξανδρος Μεσσήνης

Πανεπιστήμιο Ιωαννίνων

PP04: Sex-dependent Biobehavioral Profiling of the Fmr1 KO Rat Model: Evaluating the Therapeutic Efficacy of Cannabidiol

Ιωάννα Καρανταλή

Φοιτήτρια Βιολογικού

PP05: NF-κB pathway variants as predictors of response to anti-IL17 therapy in psoriasis.

Δημήτριος Χαρέμης

Εφαρμοσμένα Μαθηματικά

PP06: PK Modelling of Brain Exposure to an Angiotensin II Type 2 Receptor Antagonist, EMA401

Γεώργιος Σιββάς

University of Patras

PP07: Investigation of the role of the small GTPase RhoA on breast cancer-induced pre-metastatic niche

Νεφέλη Κώστα

Φοιτήτρια

PP08: Biological Implications of Phenolic Excipients in Insulin Formulations

Μαγδαληνή Τσόλκα

Pharmacology

PP09: Association of MTHFR polymorphisms rs1801133 and rs1801131 with childhood obesity.

Βασίλειος Κασάπης

Μεταπτυχιακός Φοιτητής

PP10: FTIR Spectroscopic Monitoring of Pharmacological Response to D-VRd Induction Therapy and ASCT in Multiple Myeloma: A Clinical Case Study

Michel Janho

Department Of Clinical Pharmacology, University Of Thessaly

PP11: Investigating the correlation of Interleukin-6 plasma levels with schizophrenia

Ιλεάνα Θεοφίλη

National and Kapodistrian University of Athens

PP12: Optimizing bevacizumab treatment in Cancer Patients Using Machine and Deep Learning

Ειρήνη Μαλλικοπούλου

Διδακτορική Φοιτήτρια

PP13: Liposomal Encapsulation Enhances Stability of Bacteriophage K and Demonstrates Cytocompatibility in vitro

Ιωάννα Σοφία Θεοφυλάτου

Προπτυχιακή φοιτήτρια

PP14: Comparative preclinical evaluation of novel anticancer compounds targeting the MYC oncoprotein

Ιωάννης Μπιμπιδάκης

Φαρμακευτική Τεχνολογία

PP15: In Vitro Assessment of Cytotoxicity and the Potential Protective Effects of Water-Soluble Hydrolyzed Clinoptilolite Zeolite Against Cadmium-Induced Cytotoxicity

Μαρία Γιαννακοπούλου

University of Patras

PP16: Insights into RhoA-RhoB interplay in the vascular endothelium

Κατερίνα Αποστολάκη

PhD Candidate

PP17: Genetic Variability in Vascular Endothelial Growth Factor A and Risk of Psoriasis

Δήμητρα Ιωάννα Λαμπροπούλου

Department of Nutritional Science and Dietetics, School of Health Sciences, University of the Peloponnese, Kalamata

PP18: Evaluation of a Clinical Decision Support System for Optimizing Total Parenteral Nutrition in Adult Patients with Cancer.

Γεωργία Ράγια

School of Pharmacy, Aristotle University of Thessaloniki

PP19: Development of new nerve agent mimics and their pharmacological characterization

Αντωνία Κουνελάκη

Biomedical Research Foundation Academy of Athens

PP20: Integrated LC-MS/MS Approaches for Intracellular Drug Uptake and Protein Target Quantification/Ablation in PC3 Cells

Ελένη Μαύρου

Biochemist/ Biotechnologist

PP21: Phosphoethanolamine and other related diagnostic biomarkers for Hypophosphatasia in Adults: An LC-MS/MS Approach

Κωνσταντίνος Παπαδόπουλος

Προπτυχιακός Φοιτητής Ιατρικής Και Υποψήφιος Διδάκτωρ Ιατρικής

PP22: Pharmacological properties of a novel non-peptide CRF1R ligand

Ευγενία Γιαννακοπούλου

Surgeon – Endocrine Surgeon – Mastologist, Clinical Pharmacologist

PP23: Pharmacological applications of exosomes in pancreatic adenocarcinoma treatment: Systematic Review

Ελπινίκη Αποστολίδου

Προπτυχιακός Φοιτητής ΑΠΘ

PP24: Evaluation of novel therapeutic PPI dendrimers as anti-prion agents in a murine model

Αλεξάνδρα Λαμπροπούλου

Χημικός

PP25: Targeting the ‘Undruggable’ c-MYC: Development and Evaluation of Novel PROTAC Degraders

Καριοφύλλης Καραμπέρης

Φαρμακευτική

PP26: Precision dosing of venlafaxine in Greek psychiatric patients through pharmacogenomics and machine learning-based modelling

Κωνσταντίνος Παπαδημάτος

Laboratory of Molecular Pharmacology, Department of Pharmacy, School of Health Sciences, University of Patras

PP27: Elucidation of the mechanism through which a peptide against cell surface nucleolin inhibits VEGFA-induced endothelial cell activation

Κωνσταντίνος Παπαδημάτος

Laboratory of Molecular Pharmacology, Department of Pharmacy, School of Health Sciences, University of Patras

PP28: Investigating the role of pleiotrophin in lung adenocarcinoma growth in vivo

Ιωάννα Νικολάου

ΦΑΡΜΑΚΟΠΟΙΟΣ

PP29: In vitro evaluation of artemisinin-azole hybrid molecules reveals a potent lead candidate against resistant Candida species

Χαράλαμπος Μπάκας

Φαρμακευτικη

PP30: Anthocyanins as Protective Agents for CNS damage in a Multiple Sclerosis Murine Model

Άννα Τσιρώνη

University of Patras

PP31: The Role of Genetic and Clinical Factors in Tacrolimus Pharmacokinetics

Βαΐα Σγουρή

University Of Thessaly

PP32: Long-Term Neurobehavioral Impairment Following Systemic Inflammation: A Rat Model of Sepsis-Associated Encephalopathy

Γιώτα Τσοτσόκου

Department Of Medicine, Lab Of Physiology, University Of Patras

PP33: Dopamine Differentially Modulates Sharp Wave–Ripple Activity Along the Dorsal–Ventral Axis of the Hippocampus via Receptor-Specific Mechanisms.

Αθηνά Μήλιου

Υποψήφια Διδάκτορας

PP34: Hippocampal Sharp Wave-Ripple Activity Is Resistant to Acute Cannabinoid Modulation Despite Robust CB1 Receptor Expression

Θένια Πραντίκου

Φυσιολογία

PP35: RGS4 Is Required for κ-Opioid Receptor-Mediated Suppression of Hippocampal Long-Term Potentiation In Vivo

Μαργαρίτα Λαμπροπούλου

University Of Patras

PP36: Cholinergic Modulation of Sharp-Wave Activity Along the Dorsoventral Axis of the Hippocampus: Differential Roles of M1 and M4 Receptors

Κωνσταντίνος Σαλαγιάννης

Pharmacist

PP37: Regulation of MPST expression in adipocytes by obesity-related stimuli

Χαράλαμπος Λ Κανδηλάκης

School of Health Sciences, University of Patras

PP38: Serotonergic Modulation of Sharp Waves Across the Dorsoventral Axis of the Hippocampus.

Αθηνά Μουζή

Προπτυχιακή Φοιτήτρια

PP39: Caffeine Enhances Hippocampal Excitability and Sharp Wave–Ripple Activity via A1 Receptor Blockade Along the Dorsoventral Axis.

Κανελλίνα Τσιακοπούλου

University of Patras

PP40: A multi-property study of Lamotrigine-Citric acid co-crystals

Σοφία Χατζηαντωνίου

Department of Pharmacy, University of Patras

PP41: Design and Biological Evaluation of Liposome-Based Cosmetic Serums: Linking Composition to Cellular Response and Collagen Modulation

Χρυσή Χαϊκάλη

University Of Patras

PP42: Synthesis, Characterization, and Comparative Antimicrobial Evaluation of Free and Lipid-Encapsulated, Selenium and Silver-Selenium Nanoparticles

Παρασκευάς Ζάμπας

Biomedical Research Foundation of the Academy of Athens (BRFAA)

PP43: MPST deletion improves the circulating lipidemic profile and attenuates atherosclerosis in Apoe knockout mice

Άγγελος Κονταρίνης

University of Patras

PP44: Novel 1H-Pyrazolo[3,4-c]pyridin-7(6H)-one derivatives as soluble Guanylyl Cyclase (sGC) stimulators: Pharmacological characterization in vascular smooth muscle cells

Βασιλική Μπίρμπα

University of Patras

PP45: Investigation of natural deep eutectic solvents (NADES) for the recovery of antioxidant compounds from medicinal plants (Cannabis sativa L. & Cistus creticus L.)

Πελαγία Τριγώνη

ΠΡΟΠΤΥΧΙΑΚΗ ΦΟΙΤΗΤΡΙΑ

PP46: AlphaFold-Enabled In Silico Molecular Docking of Muscarinic Antagonists on M1-M5 Receptors Reveals Novel Binding Insights and Therapeutic Synergies for COPD Management

Κωνσταντίνος Δήμας

Καθηγητής Φαρμακολογίας, Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή

Πανεπιστήμιο Θεσσαλίας

PP47: Advances in the Anticancer Evaluation of Sclareol-Based Semisynthetic Compounds

Κωνσταντίνος Δήμας

Καθηγητής Φαρμακολογίας, Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή

Πανεπιστήμιο Θεσσαλίας

PP48: Development, Optimization, and Validation of an HPLC–DAD Method for Quantifying Meropenem and Ertapenem in Human Serum

Georgia Kakafoni

University of Patras, Pharmacology Laboratory

PP49: Icosapent Ethyl and Residual Cardiovascular Risk: Findings in LDL Receptor-Deficient Mice

Βικτώρια Μπαρνιά

PhD Student

PP50: Investigation of the effect of bradykinin B2 receptor activation on hypercholesterolemia management and cardiovascular risk reduction.

Maria Alemi

University Of Patras

Συνεδρία poster – Ελαφρύ γεύμα

Speaker

PP01: The Role of Apolipoprotein A2 in Lipoprotein Metabolism, Development of Obesity, and Cardiovascular Disease

PP02: Developement of Novel Cinnamic Acid Derivatives as Promising Agents for Neurodegenerative Disorders

PP03: Platelet/Lymphocyte, Neutrophil/Lymphocyte, Monocyte/Lymphocyte Ratios and Systemic Immune-inflammation Index in Schizophrenia

PP04: Sex-dependent Biobehavioral Profiling of the Fmr1 KO Rat Model: Evaluating the Therapeutic Efficacy of Cannabidiol

PP05: NF-κB pathway variants as predictors of response to anti-IL17 therapy in psoriasis.

PP06: PK Modelling of Brain Exposure to an Angiotensin II Type 2 Receptor Antagonist, EMA401

PP07: Investigation of the role of the small GTPase RhoA on breast cancer-induced pre-metastatic niche

PP08: Biological Implications of Phenolic Excipients in Insulin Formulations

PP09: Association of MTHFR polymorphisms rs1801133 and rs1801131 with childhood obesity.

PP10: FTIR Spectroscopic Monitoring of Pharmacological Response to D-VRd Induction Therapy and ASCT in Multiple Myeloma: A Clinical Case Study

PP11: Investigating the correlation of Interleukin-6 plasma levels with schizophrenia

PP12: Optimizing bevacizumab treatment in Cancer Patients Using Machine and Deep Learning

PP13: Liposomal Encapsulation Enhances Stability of Bacteriophage K and Demonstrates Cytocompatibility in vitro

PP14: Comparative preclinical evaluation of novel anticancer compounds targeting the MYC oncoprotein

PP15: In Vitro Assessment of Cytotoxicity and the Potential Protective Effects of Water-Soluble Hydrolyzed Clinoptilolite Zeolite Against Cadmium-Induced Cytotoxicity

PP16: Insights into RhoA-RhoB interplay in the vascular endothelium

PP17: Genetic Variability in Vascular Endothelial Growth Factor A and Risk of Psoriasis

PP18: Evaluation of a Clinical Decision Support System for Optimizing Total Parenteral Nutrition in Adult Patients with Cancer.

PP19: Development of new nerve agent mimics and their pharmacological characterization

PP20: Integrated LC-MS/MS Approaches for Intracellular Drug Uptake and Protein Target Quantification/Ablation in PC3 Cells

PP21: Phosphoethanolamine and other related diagnostic biomarkers for Hypophosphatasia in Adults: An LC-MS/MS Approach

PP22: Pharmacological properties of a novel non-peptide CRF1R ligand

PP23: Pharmacological applications of exosomes in pancreatic adenocarcinoma treatment: Systematic Review

PP24: Evaluation of novel therapeutic PPI dendrimers as anti-prion agents in a murine model

PP25: Targeting the ‘Undruggable’ c-MYC: Development and Evaluation of Novel PROTAC Degraders

PP26: Precision dosing of venlafaxine in Greek psychiatric patients through pharmacogenomics and machine learning-based modelling

PP27: Elucidation of the mechanism through which a peptide against cell surface nucleolin inhibits VEGFA-induced endothelial cell activation

PP28: Investigating the role of pleiotrophin in lung adenocarcinoma growth in vivo

PP29: In vitro evaluation of artemisinin-azole hybrid molecules reveals a potent lead candidate against resistant Candida species

PP30: Anthocyanins as Protective Agents for CNS damage in a Multiple Sclerosis Murine Model

PP31: The Role of Genetic and Clinical Factors in Tacrolimus Pharmacokinetics

PP32: Long-Term Neurobehavioral Impairment Following Systemic Inflammation: A Rat Model of Sepsis-Associated Encephalopathy

PP33: Dopamine Differentially Modulates Sharp Wave–Ripple Activity Along the Dorsal–Ventral Axis of the Hippocampus via Receptor-Specific Mechanisms.

PP34: Hippocampal Sharp Wave-Ripple Activity Is Resistant to Acute Cannabinoid Modulation Despite Robust CB1 Receptor Expression

PP35: RGS4 Is Required for κ-Opioid Receptor-Mediated Suppression of Hippocampal Long-Term Potentiation In Vivo

PP36: Cholinergic Modulation of Sharp-Wave Activity Along the Dorsoventral Axis of the Hippocampus: Differential Roles of M1 and M4 Receptors

PP37: Regulation of MPST expression in adipocytes by obesity-related stimuli

PP38: Serotonergic Modulation of Sharp Waves Across the Dorsoventral Axis of the Hippocampus.

PP39: Caffeine Enhances Hippocampal Excitability and Sharp Wave–Ripple Activity via A1 Receptor Blockade Along the Dorsoventral Axis.

PP40: A multi-property study of Lamotrigine-Citric acid co-crystals

PP41: Design and Biological Evaluation of Liposome-Based Cosmetic Serums: Linking Composition to Cellular Response and Collagen Modulation

PP42: Synthesis, Characterization, and Comparative Antimicrobial Evaluation of Free and Lipid-Encapsulated, Selenium and Silver-Selenium Nanoparticles

PP43: MPST deletion improves the circulating lipidemic profile and attenuates atherosclerosis in Apoe knockout mice

PP44: Novel 1H-Pyrazolo[3,4-c]pyridin-7(6H)-one derivatives as soluble Guanylyl Cyclase (sGC) stimulators: Pharmacological characterization in vascular smooth muscle cells

PP45: Investigation of natural deep eutectic solvents (NADES) for the recovery of antioxidant compounds from medicinal plants (Cannabis sativa L. & Cistus creticus L.)

PP46: AlphaFold-Enabled In Silico Molecular Docking of Muscarinic Antagonists on M1-M5 Receptors Reveals Novel Binding Insights and Therapeutic Synergies for COPD Management

PP47: Advances in the Anticancer Evaluation of Sclareol-Based Semisynthetic Compounds

PP48: Development, Optimization, and Validation of an HPLC–DAD Method for Quantifying Meropenem and Ertapenem in Human Serum

PP49: Icosapent Ethyl and Residual Cardiovascular Risk: Findings in LDL Receptor-Deficient Mice

PP50: Investigation of the effect of bradykinin B2 receptor activation on hypercholesterolemia management and cardiovascular risk reduction.

PP51: Study of the Functional Interaction Between Apolipoprotein A2 and the LDL Receptor in Lipoprotein and Adipose Tissue Metabolism